Why One Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

💡 Analyst expects $PFE stock to rise 38% due to optimistic outlook on its pipeline.

The Federal Reserve delivered a hawkish surprise on Wednesday, signaling that interest rate cuts remain further away than markets had hoped. Fed Chair Jerome Powell told reporters that the central bank needs "greater confidence" that inflation is sustainably declining before it will consider easing policy.

The 10-year Treasury yield surged to 4.8% in the aftermath, its highest level since October 2023. $TLT fell sharply as bond traders repriced the timing of the first cut from March to June.

Pfizer's Pipeline Gains Momentum

A recent report from Wall Street analyst Brian Orelli, who covers $PFE for Charles Schwab, highlights the company's impressive pipeline, which includes several promising candidates in late-stage trials. Orelli is optimistic about the potential of these drugs, citing their strong clinical data and competitive positioning in their respective markets.

Positive Catalysts Ahead

Several positive catalysts are on the horizon for $PFE, including the expected FDA approval of its COVID-19 vaccine booster, which could provide a significant revenue boost. Additionally, the company's ongoing efforts to expand its presence in the biotech space through strategic acquisitions and partnerships are likely to drive long-term growth.

Valuation and Sentiment

Despite its strong fundamentals, $PFE's stock has been somewhat underwhelming investors lately. However, with a forward P/E ratio of 12.5x, the stock appears to be undervalued compared to its peers. Moreover, the company's impressive pipeline and positive sentiment from analysts and investors suggest that the stock is poised for a significant upside.

What It Means for Investors